{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=laboratory+correlative+studies&page=4", "query": { "intervention": "laboratory correlative studies", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 2585, "total_pages": 259, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=laboratory+correlative+studies&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=laboratory+correlative+studies&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T19:25:16.724Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00362882", "title": "Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Recurrent Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 81, "start_date": "2006-07", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-10-05T19:25:16.724Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00362882" }, { "nct_id": "NCT01385280", "title": "Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Estrogen Receptor-positive Breast Cancer", "Progesterone Receptor Positive Tumor", "Recurrent Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "therapeutic estradiol", "type": "BIOLOGICAL" }, { "name": "exemestane", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "enzyme-linked immunosorbent assay", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 13, "start_date": "2011-02", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2018-10-17", "last_synced_at": "2026-10-05T19:25:16.724Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01385280" }, { "nct_id": "NCT01789827", "title": "Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Stage IV Skin Melanoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2014-03", "completion_date": "2018-06-27", "has_results": false, "last_update_posted_date": "2019-08-05", "last_synced_at": "2026-10-05T19:25:16.724Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01789827" }, { "nct_id": "NCT03258554", "title": "Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Head and Neck Squamous Cell Carcinoma", "Hypopharyngeal Squamous Cell Carcinoma", "Laryngeal Squamous Cell Carcinoma", "Oral Cavity Squamous Cell Carcinoma", "Oropharyngeal Squamous Cell Carcinoma", "Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Squamous Cell Carcinoma of Unknown Primary", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Hypopharyngeal Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVB Hypopharyngeal Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Lip and Oral Cavity Cancer AJCC v8", "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 196, "start_date": "2018-04-03", "completion_date": "2025-09-04", "has_results": true, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-05T19:25:16.724Z", "location_count": 252, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 193 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03258554" }, { "nct_id": "NCT03012880", "title": "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2017-04-20", "completion_date": "2022-12-15", "has_results": true, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-10-05T19:25:16.724Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03012880" }, { "nct_id": "NCT00896961", "title": "EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage I Adult Soft Tissue Sarcoma", "Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage II Adult Soft Tissue Sarcoma", "Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Adult Soft Tissue Sarcoma", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity" ], "interventions": [ { "name": "EF5", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2001-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-10-05T19:25:16.724Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00896961" }, { "nct_id": "NCT00071942", "title": "Vaccine Therapy in Treating Patients With Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "recombinant vaccinia-MUC1 vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant vaccinia-TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2003-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-11", "last_synced_at": "2026-10-05T19:25:16.724Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00071942" }, { "nct_id": "NCT01253642", "title": "Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone-Resistant Prostate Cancer", "Metastatic Prostatic Adenocarcinoma", "Prostate Adenocarcinoma", "Recurrent Prostate Carcinoma" ], "interventions": [ { "name": "Biopsy of Prostate", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Phenelzine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 11, "start_date": "2010-07-12", "completion_date": "2017-09-15", "has_results": true, "last_update_posted_date": "2019-10-02", "last_synced_at": "2026-10-05T19:25:16.724Z", "location_count": 3, "location_summary": "Portland, Oregon • Seattle, Washington", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01253642" }, { "nct_id": "NCT03563651", "title": "Collection of Blood, Urine, and Stool to Monitor MetastaticColorectal Cancers", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stage III Colorectal Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2014-02-06", "completion_date": "2020-05-28", "has_results": false, "last_update_posted_date": "2021-11-18", "last_synced_at": "2026-10-05T19:25:16.724Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563651" }, { "nct_id": "NCT01148966", "title": "Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Oligodendroglioma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Mixed Glioma", "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "aminolevulinic acid", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2010-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-10-05T19:25:16.724Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01148966" } ] }